{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:41:10Z","timestamp":1768030870497,"version":"3.49.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Aging","award":["1R01AG067476"],"award-info":[{"award-number":["1R01AG067476"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amyloid-beta (A\u03b2) toxic oligomers are critical early players in the molecular pathology of Alzheimer\u2019s disease (AD). We have developed a Soluble Oligomer Binding Assay (SOBA-AD) for detection of these A\u03b2 oligomers that contain \u03b1-sheet secondary structure that discriminates plasma samples from patients on the AD continuum from non-AD controls. We tested 265 plasma samples from two independent cohorts to investigate the performance of SOBA-AD. Testing was performed at two different sites, with different personnel, reagents, and instrumentation. Across two cohorts, SOBA-AD discriminated AD patients from cognitively unimpaired (CU) subjects with 100% sensitivity,\u2009&gt;\u200995% specificity, and\u2009&gt;\u200998% area under the curve (AUC) (95% CI 0.95\u20131.00). A SOBA-AD positive readout, reflecting \u03b1-sheet toxic oligomer burden, was found in AD patients, and not in controls, providing separation of the two populations, aside from 5 SOBA-AD positive controls. Based on an earlier SOBA-AD study, the A\u03b2 oligomers detected in these CU subjects may represent preclinical cases of AD. The results presented here support the value of SOBA-AD as a promising blood-based tool for the detection and confirmation of AD.<\/jats:p>","DOI":"10.1038\/s41598-024-57107-w","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T14:02:20Z","timestamp":1712239340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Performance of SOBA-AD blood test in discriminating Alzheimer\u2019s disease patients from cognitively unimpaired controls in two independent cohorts"],"prefix":"10.1038","volume":"14","author":[{"given":"Amy","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Daggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"57107_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol. Med. 8, 595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210 (2016).","journal-title":"EMBO Mol. Med."},{"key":"57107_CR2","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The amyloid-\u03b2 oligomer hypothesis: Beginning of the third decade. J. Alzheimers Dis. 64, S567\u2013S610. https:\/\/doi.org\/10.3233\/JAD-179941 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"57107_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jnc.15007","volume":"154","author":"S Li","year":"2020","unstructured":"Li, S. & Selkoe, D. J. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A\u03b2 oligomers from Alzheimer\u2019s brain. J. Neurochem. 154, 583\u2013597. https:\/\/doi.org\/10.1111\/jnc.15007 (2020).","journal-title":"J. Neurochem."},{"key":"57107_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2009.05.024","volume":"35","author":"JL Tomic","year":"2009","unstructured":"Tomic, J. L., Pensalfini, A., Head, E. & Glabe, C. G. Soluble fibrillar oligomer levels are elevated in Alzheimer\u2019s disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 35, 352\u2013358. https:\/\/doi.org\/10.1016\/j.nbd.2009.05.024 (2009).","journal-title":"Neurobiol. Dis."},{"key":"57107_CR5","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1073\/pnas.96.6.3228","volume":"96","author":"AY Hsia","year":"1999","unstructured":"Hsia, A. Y. et al. Plaque-independent disruption of neural circuits in Alzheimer\u2019s disease mouse models. Proc. Natl. Acad. Sci. USA 96, 3228\u20133233. https:\/\/doi.org\/10.1073\/pnas.96.6.3228 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57107_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/s0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo, S. et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409\u2013421. https:\/\/doi.org\/10.1016\/s0896-6273(03)00434-3 (2003).","journal-title":"Neuron"},{"key":"57107_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","volume":"29","author":"FG De Felice","year":"2008","unstructured":"De Felice, F. G. et al. Alzheimer\u2019s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging 29, 1334\u20131347. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.02.029 (2008).","journal-title":"Neurobiol. Aging"},{"key":"57107_CR8","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","volume":"30","author":"H Zempel","year":"2010","unstructured":"Zempel, H., Thies, E., Mandelkow, E. & Mandelkow, E. M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30, 11938\u201311950. https:\/\/doi.org\/10.1523\/JNEUROSCI.2357-10.2010 (2010).","journal-title":"J. Neurosci."},{"key":"57107_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1126\/science.1242077","volume":"341","author":"T Kim","year":"2013","unstructured":"Kim, T. et al. Human LilrB2 is a \u03b2-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer\u2019s model. Science 341, 1399\u20131404. https:\/\/doi.org\/10.1126\/science.1242077 (2013).","journal-title":"Science"},{"key":"57107_CR10","first-page":"291","volume":"91","author":"A Leuzy","year":"2018","unstructured":"Leuzy, A., Heurling, K., Ashton, N. J., Sch\u00f6ll, M. & Zimmer, E. R. Detection of Alzheimer\u2019s disease. Yale J. Biol. Med. 91, 291\u2013300 (2018).","journal-title":"Yale J. Biol. Med."},{"key":"57107_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack, C. R. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207\u2013216. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0 (2013).","journal-title":"Lancet Neurol."},{"key":"57107_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13311-016-0481-z","volume":"14","author":"SE Counts","year":"2017","unstructured":"Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E. & Mufson, E. J. Biomarkers for the early detection and progression of Alzheimer\u2019s disease. Neurotherapeutics 14, 35\u201353. https:\/\/doi.org\/10.1007\/s13311-016-0481-z (2017).","journal-title":"Neurotherapeutics"},{"key":"57107_CR13","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1073\/pnas.0401781101","volume":"101","author":"RS Armen","year":"2004","unstructured":"Armen, R. S., DeMarco, M. L., Alonso, D. O. & Daggett, V. Pauling and Corey\u2019s alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. Proc. Natl. Acad. Sci. USA 101, 11622\u201311627. https:\/\/doi.org\/10.1073\/pnas.0401781101 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57107_CR14","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.str.2004.08.005","volume":"12","author":"RS Armen","year":"2004","unstructured":"Armen, R. S., Alonso, D. O. & Daggett, V. Anatomy of an amyloidogenic intermediate: Conversion of beta-sheet to alpha-sheet structure in transthyretin at acidic pH. Structure 12, 1847\u20131863. https:\/\/doi.org\/10.1016\/j.str.2004.08.005 (2004).","journal-title":"Structure"},{"key":"57107_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1021\/ar0500719","volume":"39","author":"V Daggett","year":"2006","unstructured":"Daggett, V. Alpha-sheet: The toxic conformer in amyloid diseases?. Acc. Chem. Res. 39, 594\u2013602. https:\/\/doi.org\/10.1021\/ar0500719 (2006).","journal-title":"Acc. Chem. Res."},{"key":"57107_CR16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01681","volume":"3","author":"G Hopping","year":"2014","unstructured":"Hopping, G. et al. Designed \u03b1-sheet peptides inhibit amyloid formation by targeting toxic oligomers. Elife 3, e01681. https:\/\/doi.org\/10.7554\/eLife.01681 (2014).","journal-title":"Elife"},{"key":"57107_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1021\/acs.biochem.7b00345","volume":"57","author":"NL Maris","year":"2018","unstructured":"Maris, N. L., Shea, D., Bleem, A., Bryers, J. D. & Daggett, V. Chemical and physical variability in structural isomers of an L\/D \u03b1-sheet peptide designed to inhibit amyloidogenesis. Biochemistry 57, 507\u2013510. https:\/\/doi.org\/10.1021\/acs.biochem.7b00345 (2018).","journal-title":"Biochemistry"},{"key":"57107_CR18","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.jmb.2016.03.013","volume":"428","author":"J Kellock","year":"2016","unstructured":"Kellock, J., Hopping, G., Caughey, B. & Daggett, V. Peptides composed of alternating l- and d-amino acids inhibit amyloidogenesis in three distinct amyloid systems independent of sequence. J. Mol. Biol. 428, 2317\u20132328. https:\/\/doi.org\/10.1016\/j.jmb.2016.03.013 (2016).","journal-title":"J. Mol. Biol."},{"key":"57107_CR19","first-page":"247","volume":"91","author":"TM Bi","year":"2018","unstructured":"Bi, T. M. & Daggett, V. The role of \u03b1-sheet in amyloid oligomer aggregation and toxicity. Yale J. Biol. Med. 91, 247\u2013255 (2018).","journal-title":"Yale J. Biol. Med."},{"key":"57107_CR20","doi-asserted-by":"publisher","first-page":"8895","DOI":"10.1073\/pnas.1820585116","volume":"116","author":"D Shea","year":"2019","unstructured":"Shea, D. et al. \u03b1-Sheet secondary structure in amyloid \u03b2-peptide drives aggregation and toxicity in Alzheimer\u2019s disease. Proc. Natl. Acad. Sci. USA 116, 8895\u20138900. https:\/\/doi.org\/10.1073\/pnas.1820585116 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57107_CR21","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.220261","volume":"12","author":"T Prosswimmer","year":"2022","unstructured":"Prosswimmer, T. & Daggett, V. The role of \u03b1-sheet structure in amyloidogenesis: Characterization and implications. Open Biol. 12, 220261. https:\/\/doi.org\/10.1098\/rsob.220261 (2022).","journal-title":"Open Biol."},{"key":"57107_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213157119","volume":"119","author":"D Shea","year":"2022","unstructured":"Shea, D. et al. SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. Proc. Natl. Acad. Sci. USA 119, e2213157119. https:\/\/doi.org\/10.1073\/pnas.2213157119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57107_CR23","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 18, 2669\u20132686. https:\/\/doi.org\/10.1002\/alz.12756 (2022).","journal-title":"Alzheimers Dement."},{"key":"57107_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.neuropsych.12120402","volume":"26","author":"MM Witte","year":"2014","unstructured":"Witte, M. M. et al. Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimer\u2019s disease dementia. J. Neuropsychiatry Clin. Neurosci. 26, 214\u2013220. https:\/\/doi.org\/10.1176\/appi.neuropsych.12120402 (2014).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"57107_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J. Neuropathol. Exp. Neurol. 71, 266\u2013273. https:\/\/doi.org\/10.1097\/NEN.0b013e31824b211b (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"57107_CR26","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/jnnp-2014-307662","volume":"85","author":"RM Ahmed","year":"2014","unstructured":"Ahmed, R. M. et al. Biomarkers in dementia: Clinical utility and new directions. J. Neurol. Neurosurg. Psychiatry 85, 1426\u20131434. https:\/\/doi.org\/10.1136\/jnnp-2014-307662 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"57107_CR27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3233\/JAD-170680","volume":"62","author":"M Bjerke","year":"2018","unstructured":"Bjerke, M. & Engelborghs, S. Cerebrospinal fluid biomarkers for early and differential Alzheimer\u2019s disease diagnosis. J. Alzheimers Dis. 62, 1199\u20131209. https:\/\/doi.org\/10.3233\/JAD-170680 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"57107_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson, O., Lehmann, S., Otto, M., Zetterberg, H. & Lewczuk, P. Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimers Res. Ther. 11, 34. https:\/\/doi.org\/10.1186\/s13195-019-0485-0 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"57107_CR29","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage, M. J. et al. A sensitive a\u03b2 oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J. Neurosci. 34, 2884\u20132897. https:\/\/doi.org\/10.1523\/JNEUROSCI.1675-13.2014 (2014).","journal-title":"J. Neurosci."},{"key":"57107_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-015-0100-y","volume":"7","author":"T Yang","year":"2015","unstructured":"Yang, T. et al. A highly sensitive novel immunoassay specifically detects low levels of soluble A\u03b2 oligomers in human cerebrospinal fluid. Alzheimers Res. Ther. 7, 14. https:\/\/doi.org\/10.1186\/s13195-015-0100-y (2015).","journal-title":"Alzheimers Res. Ther."},{"key":"57107_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"57107_CR32","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 384, 1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708 (2021).","journal-title":"N. Engl. J. Med."},{"key":"57107_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239 (2023).","journal-title":"JAMA"},{"key":"57107_CR34","unstructured":"Food and Drug Administration. Evaluation of Automatic Class III Designation for Lumipulse G \u03b2-Amyloid Ratio (1-42\/1-40) Decision Summary. (Accessed 4 May 2022) https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN200072.pdf."},{"key":"57107_CR35","unstructured":"Food and Drug Administration. K221842 Elecsys \u03b2-Amyloid (1-42) CSF II, Elecsys Phospho-tau (181P) CSF Summary. (Accessed 7 Dec 2022) https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf22\/K221842.pdf."},{"key":"57107_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126355","author":"M Tolar","year":"2021","unstructured":"Tolar, M., Hey, J., Power, A. & Abushakra, S. Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22126355 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"57107_CR37","doi-asserted-by":"publisher","first-page":"14745","DOI":"10.1073\/pnas.0905127106","volume":"106","author":"K Ono","year":"2009","unstructured":"Ono, K., Condron, M. M. & Teplow, D. B. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc. Natl. Acad. Sci. USA 106, 14745\u201314750. https:\/\/doi.org\/10.1073\/pnas.0905127106 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57107_CR38","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/jcb.30141","volume":"122","author":"P Madhu","year":"2021","unstructured":"Madhu, P. & Mukhopadhyay, S. Distinct types of amyloid-\u03b2 oligomers displaying diverse neurotoxicity mechanisms in Alzheimer\u2019s disease. J. Cell Biochem. 122, 1594\u20131608. https:\/\/doi.org\/10.1002\/jcb.30141 (2021).","journal-title":"J. Cell Biochem."},{"key":"57107_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00401-018-1846-7","volume":"136","author":"W Hong","year":"2018","unstructured":"Hong, W. et al. Diffusible, highly bioactive oligomers represent a critical minority of soluble A\u03b2 in Alzheimer\u2019s disease brain. Acta Neuropathol. 136, 19\u201340. https:\/\/doi.org\/10.1007\/s00401-018-1846-7 (2018).","journal-title":"Acta Neuropathol."},{"key":"57107_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40478-019-0777-4","volume":"7","author":"S De","year":"2019","unstructured":"De, S. et al. Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer\u2019s disease progression. Acta Neuropathol. Commun. 7, 120. https:\/\/doi.org\/10.1186\/s40478-019-0777-4 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"57107_CR41","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41467-019-09477-3","volume":"10","author":"S De","year":"2019","unstructured":"De, S. et al. Different soluble aggregates of A\u03b242 can give rise to cellular toxicity through different mechanisms. Nat. Commun. 10, 1541. https:\/\/doi.org\/10.1038\/s41467-019-09477-3 (2019).","journal-title":"Nat. Commun."},{"key":"57107_CR42","doi-asserted-by":"publisher","first-page":"fcab147","DOI":"10.1093\/braincomms\/fcab147","volume":"3","author":"DI Sideris","year":"2021","unstructured":"Sideris, D. I. et al. Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer\u2019s disease. Brain Commun. 3, fcab147. https:\/\/doi.org\/10.1093\/braincomms\/fcab147 (2021).","journal-title":"Brain Commun."},{"key":"57107_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.expneurol.2009.09.001","volume":"223","author":"RC Gaspar","year":"2010","unstructured":"Gaspar, R. C. et al. Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. Exp. Neurol. 223, 394\u2013400. https:\/\/doi.org\/10.1016\/j.expneurol.2009.09.001 (2010).","journal-title":"Exp. Neurol."},{"key":"57107_CR44","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1073\/pnas.0511256103","volume":"103","author":"RA Bodner","year":"2006","unstructured":"Bodner, R. A. et al. Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington\u2019s and Parkinson\u2019s diseases. Proc. Natl. Acad. Sci. USA 103, 4246\u20134251. https:\/\/doi.org\/10.1073\/pnas.0511256103 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57107_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2850","volume":"13","author":"D Ruan","year":"2023","unstructured":"Ruan, D. & Sun, L. Amyloid-\u03b2 PET in Alzheimer\u2019s disease: A systematic review and Bayesian meta-analysis. Brain Behav. 13, e2850. https:\/\/doi.org\/10.1002\/brb3.2850 (2023).","journal-title":"Brain Behav."},{"key":"57107_CR46","unstructured":"The Swedish BioFINDER Study, https:\/\/biofinder.se\/ (2023)."},{"key":"57107_CR47","unstructured":"Alzheimer\u2019s Disease Neuroimaging Initiative, https:\/\/adni.loni.usc.edu\/ (2017)."},{"key":"57107_CR48","unstructured":"The Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing, https:\/\/aibl.csiro.au\/ (2006)."},{"key":"57107_CR49","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/alz.12422","volume":"18","author":"DP Veitch","year":"2022","unstructured":"Veitch, D. P. et al. Using the Alzheimer\u2019s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer\u2019s disease. Alzheimers Dement. 18, 824\u2013857. https:\/\/doi.org\/10.1002\/alz.12422 (2022).","journal-title":"Alzheimers Dement."},{"key":"57107_CR50","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jalz.2010.03.009","volume":"6","author":"KA Ellis","year":"2010","unstructured":"Ellis, K. A. et al. Addressing population aging and Alzheimer\u2019s disease through the Australian imaging biomarkers and lifestyle study: Collaboration with the Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimers Dement. 6, 291\u2013296. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.009 (2010).","journal-title":"Alzheimers Dement."},{"key":"57107_CR51","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 280\u2013292. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003 (2011).","journal-title":"Alzheimers Dement."},{"key":"57107_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."},{"key":"57107_CR53","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois, B. et al. Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 12, 292\u2013323. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.002 (2016).","journal-title":"Alzheimers Dement."},{"key":"57107_CR54","doi-asserted-by":"publisher","first-page":"569","DOI":"10.14283\/jpad.2022.85","volume":"9","author":"D Angioni","year":"2022","unstructured":"Angioni, D. et al. Blood biomarkers from research use to clinical practice: What must be done? A report from the EU\/US CTAD task force. J. Prev. Alzheimers Dis. 9, 569\u2013579. https:\/\/doi.org\/10.14283\/jpad.2022.85 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"57107_CR55","doi-asserted-by":"publisher","first-page":"418","DOI":"10.14283\/jpad.2023.68","volume":"10","author":"D Angioni","year":"2023","unstructured":"Angioni, D. et al. Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU\/US CTAD task force. J. Prev. Alzheimers Dis. 10, 418\u2013425. https:\/\/doi.org\/10.14283\/jpad.2023.68 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"57107_CR56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation. Lancet Neurol. 21, 66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6 (2022).","journal-title":"Lancet Neurol."},{"key":"57107_CR57","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: Towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734. https:\/\/doi.org\/10.1016\/S1474-4422(22)00168-5 (2022).","journal-title":"Lancet Neurol."},{"key":"57107_CR58","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n, J. et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 17, 1145\u20131156. https:\/\/doi.org\/10.1002\/alz.12283 (2021).","journal-title":"Alzheimers Dement."},{"key":"57107_CR59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","volume":"143","author":"DS Smirnov","year":"2022","unstructured":"Smirnov, D. S. et al. Plasma biomarkers for Alzheimer\u2019s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 143, 487\u2013503. https:\/\/doi.org\/10.1007\/s00401-022-02408-5 (2022).","journal-title":"Acta Neuropathol."},{"key":"57107_CR60","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke, M. M. et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 78, 1108\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2293 (2021).","journal-title":"JAMA Neurol."},{"key":"57107_CR61","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. Neurology 97, e1681\u2013e1694. https:\/\/doi.org\/10.1212\/WNL.0000000000012727 (2021).","journal-title":"Neurology"},{"key":"57107_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1 (2020).","journal-title":"Nat. Med."},{"key":"57107_CR63","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ana.26308","volume":"91","author":"PF Meyer","year":"2022","unstructured":"Meyer, P. F. et al. Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. Ann. Neurol. 91, 548\u2013560. https:\/\/doi.org\/10.1002\/ana.26308 (2022).","journal-title":"Ann. Neurol."},{"key":"57107_CR64","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/alz.12447","volume":"18","author":"P Chatterjee","year":"2022","unstructured":"Chatterjee, P. et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease. Alzheimers Dement. 18, 1141\u20131154. https:\/\/doi.org\/10.1002\/alz.12447 (2022).","journal-title":"Alzheimers Dement."},{"key":"57107_CR65","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w (2022).","journal-title":"Nat. Med."},{"key":"57107_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13318","author":"Y Yakoub","year":"2023","unstructured":"Yakoub, Y. et al. Longitudinal blood biomarker trajectories in preclinical Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13318 (2023).","journal-title":"Alzheimers Dement."},{"key":"57107_CR67","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562. https:\/\/doi.org\/10.1038\/s41591-022-02074-w (2022).","journal-title":"Nat. Med."},{"key":"57107_CR68","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 80, 360\u2013369. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272 (2023).","journal-title":"JAMA Neurol."},{"key":"57107_CR69","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134 (2020).","journal-title":"JAMA"},{"key":"57107_CR70","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","volume":"93","author":"PS Insel","year":"2019","unstructured":"Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322\u2013e333. https:\/\/doi.org\/10.1212\/WNL.0000000000007831 (2019).","journal-title":"Neurology"},{"key":"57107_CR71","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 19, 1913\u20131924. https:\/\/doi.org\/10.1002\/alz.12841 (2023).","journal-title":"Alzheimers Dement."},{"key":"57107_CR72","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333 (2023).","journal-title":"Brain"},{"key":"57107_CR73","doi-asserted-by":"crossref","unstructured":"Dawson, K. Biomarker Changes and their relationships to clinical efficacy outcomes in Alzheimer\u2019s Disease in Alzheimer\u2019s Association International Conference, July 19, 2023; Amsterdam, Netherlands. https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/83267.","DOI":"10.1002\/alz.083267"},{"key":"57107_CR74","doi-asserted-by":"crossref","unstructured":"Doody R. Observations on Biomarkers in Roche Abeta-targeting Monoclonal Antibody Trials in Alzheimer\u2019s Association International Conference, July 19, 2023; Amsterdam Netherlands. https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/80906.","DOI":"10.1002\/alz.080906"},{"key":"57107_CR75","doi-asserted-by":"crossref","unstructured":"Irizarry, M. C. Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker Modification in Alzheimer\u2019s Association International Conference, July 19, 2023; Amsterdam, Netherlands. https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/80907","DOI":"10.1002\/alz.080907"},{"key":"57107_CR76","doi-asserted-by":"crossref","unstructured":"Sims, J. R. Amyloid Reduction: Donanemab Perspective in Alzheimer\u2019s Association International Conference, July 19, 2023; Amsterdam, Netherlands. https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/80904.","DOI":"10.1002\/alz.080904"},{"key":"57107_CR77","unstructured":"The National Institute on Aging and the Alzheimer\u2019s Association (NIA-AA). NIA-AA Revised Clinical Criteria for Alzheimer\u2019s Disease (2023). https:\/\/aaic.alz.org\/downloads2023\/NIA-AA-Revised-Clinical-Criteria-AAIC-2023.pdf."},{"key":"57107_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/biophysica2020010","volume":"2","author":"D Shea","year":"2022","unstructured":"Shea, D. & Daggett, V. Amyloid-beta; Oligomers: Multiple moving targets. Biophysica 2, 91\u2013110. https:\/\/doi.org\/10.3390\/biophysica2020010 (2022).","journal-title":"Biophysica"},{"key":"57107_CR79","unstructured":"Roche. Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) (2019) https:\/\/www.roche.com\/media\/releases\/med-cor-2019-01-30."},{"key":"57107_CR80","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki, S. et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials. JAMA Neurol. 79, 1113\u20131121. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2909 (2022).","journal-title":"JAMA Neurol."},{"key":"57107_CR81","unstructured":"U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation Office of Disability. Racial and Ethnic Disparities in Alzheimer\u2019s Disease: A Literature Review (2014) https:\/\/aspe.hhs.gov\/sites\/default\/files\/migrated_legacy_files\/138596\/RacEthDis.pdf."},{"key":"57107_CR82","doi-asserted-by":"publisher","first-page":"388","DOI":"10.14283\/jpad.2022.50","volume":"9","author":"R Raman","year":"2022","unstructured":"Raman, R. et al. Tackling a major deficiency of diversity in Alzheimer\u2019s disease therapeutic trials: An CTAD task force report. J. Prev. Alzheimers Dis. 9, 388\u2013392. https:\/\/doi.org\/10.14283\/jpad.2022.50 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"57107_CR83","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jalz.2015.12.007","volume":"12","author":"ER Mayeda","year":"2016","unstructured":"Mayeda, E. R., Glymour, M. M., Quesenberry, C. P. & Whitmer, R. A. Inequalities in dementia iCUdence between six racial and ethnic groups over 14 years. Alzheimers Dement. 12, 216\u2013224. https:\/\/doi.org\/10.1016\/j.jalz.2015.12.007 (2016).","journal-title":"Alzheimers Dement."},{"key":"57107_CR84","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jalz.2018.07.221","volume":"15","author":"P Brewster","year":"2019","unstructured":"Brewster, P. et al. Progress and future challenges in aging and diversity research in the United States. Alzheimers Dement. 15, 995\u20131003. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.221 (2019).","journal-title":"Alzheimers Dement."},{"key":"57107_CR85","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/alz.12822","volume":"19","author":"C Gillis","year":"2023","unstructured":"Gillis, C., Montenigro, P., Nejati, M. & Maserejian, N. Estimating prevalence of early Alzheimer\u2019s disease in the United States, accounting for racial and ethnic diversity. Alzheimers Dement. 19, 1841\u20131848. https:\/\/doi.org\/10.1002\/alz.12822 (2023).","journal-title":"Alzheimers Dement."},{"key":"57107_CR86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41582-021-00589-3","volume":"18","author":"LL Barnes","year":"2022","unstructured":"Barnes, L. L. Alzheimer disease in African American individuals: Increased iCUdence or not enough data?. Nat. Rev. Neurol. 18, 56\u201362. https:\/\/doi.org\/10.1038\/s41582-021-00589-3 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"57107_CR87","unstructured":"Steenhuysen, J. Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks in Reuters (2023) https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/promising-new-alzheimers-drugs-may-benefit-whites-more-than-blacks-2023-07-31."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57107-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T10:02:23Z","timestamp":1714471343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57107-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["57107"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-57107-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC and DS. are current and former employees, respectively, of AltPep. VD is the founder and Chief Executive Officer of AltPep.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7946"}}